PDF(Pubmed)
Abstract：
UNASSIGNED: High recurrence rate of chalaziosis and serious side effects of repeated surgical excision may help increase awareness of recurrent and refractory chalaziosis as a serious disorder affecting many aspects of life. This present study was aimed to investigate the efficacy and safety of intense pulse light (IPL) therapy and meibomian gland expression (MGX) in cases of recurrent chalaziosis after excision surgery.
UNASSIGNED: Forty-two consecutive recurrent chalaziosis cases (35 patients) treated with IPL-MGX were enrolled. All patients initially underwent excision with curettage. One week after lesion excision, IPL-MGX were performed at least 3 times. Another set of age- and sex-matched consecutive cases of recurrent chalaziosis, who received excision with curettage, but went without IPL-MGX treatment, were collected to calculate recurrence rate. Treatment efficacy and safety were measured before IPL-MGX treatment and 1 month after the final treatment.
UNASSIGNED: The majority of patients received 4 sessions of IPL-MGX therapy (20 patients; 57.1%) or 3 sessions of IPL-MGX therapy (10 patients; 28.6%), resulting in a lower recurrence rate of 11.4% compared to that of recurrent chalaziosis without IPL-MGX cases (45.6%, P < 0.001). The NIBUT was significantly prolonged from 3.9 ± 1.8 to 5.1 ± 1.7 s at 4 weeks after the final treatment (P = 0.001). Similarly, mean TMH score improved and was statistically significant when compared with baseline (0.17 ± 0.07 vs. 0.21± 0.09; P = 0.008). Furthermore, meibum quality and expressibility scores significantly improved at 4 weeks following the final treatment (both P < 0.001). Other variables, such as intraocular pressure and visual acuity, remained unaffected following treatment.
UNASSIGNED: The combination of IPL treatment and MGX offers a low risk and effective option in decreasing the recurrence rate of recurrent chalaziosis by improving meibomian gland function. IPL-MGX may be considered for first-line treatment in recurrent or refractory cases post excision.
UNASSIGNED: Forty-two consecutive recurrent chalaziosis cases (35 patients) treated with IPL-MGX were enrolled. All patients initially underwent excision with curettage. One week after lesion excision, IPL-MGX were performed at least 3 times. Another set of age- and sex-matched consecutive cases of recurrent chalaziosis, who received excision with curettage, but went without IPL-MGX treatment, were collected to calculate recurrence rate. Treatment efficacy and safety were measured before IPL-MGX treatment and 1 month after the final treatment.
UNASSIGNED: The majority of patients received 4 sessions of IPL-MGX therapy (20 patients; 57.1%) or 3 sessions of IPL-MGX therapy (10 patients; 28.6%), resulting in a lower recurrence rate of 11.4% compared to that of recurrent chalaziosis without IPL-MGX cases (45.6%, P < 0.001). The NIBUT was significantly prolonged from 3.9 ± 1.8 to 5.1 ± 1.7 s at 4 weeks after the final treatment (P = 0.001). Similarly, mean TMH score improved and was statistically significant when compared with baseline (0.17 ± 0.07 vs. 0.21± 0.09; P = 0.008). Furthermore, meibum quality and expressibility scores significantly improved at 4 weeks following the final treatment (both P < 0.001). Other variables, such as intraocular pressure and visual acuity, remained unaffected following treatment.
UNASSIGNED: The combination of IPL treatment and MGX offers a low risk and effective option in decreasing the recurrence rate of recurrent chalaziosis by improving meibomian gland function. IPL-MGX may be considered for first-line treatment in recurrent or refractory cases post excision.
摘要：
未经证实：结束症的高复发率和反复手术切除的严重副作用可能有助于提高对复发性和难治性结束症的认识，这是一种严重的疾病，会影响生活的许多方面。本研究旨在研究强脉冲光（IPL）治疗和睑板腺表达（MGX）在切除手术后复发性结束症病例中的疗效和安全性。
UNASSIGNED：纳入了用IPL-MGX治疗的42例连续复发性结束症病例（35例患者）。所有患者最初都进行了刮除术切除。病灶切除后一周，IPL-MGX进行至少3次。另一组年龄和性别匹配的复发性结束炎连续病例，接受了刮宫切除术的人，但是没有IPL-MGX治疗，收集以计算复发率。在IPL-MGX治疗前和最终治疗后1个月测量治疗效果和安全性。
UNASSIGNED：大多数患者接受4次IPL-MGX治疗（20例；57.1%）或3次IPL-MGX治疗（10例；28.6%），与无IPL-MGX病例的复发性结束症相比，复发率较低，为11.4％（45.6％，P<0.001)。最终治疗后4周，NIBUT从3.9±1.8s显着延长至5.1±1.7s（P=0.001）。同样，与基线相比，平均TMH评分改善且具有统计学意义(0.17±0.07vs.0.21±0.09；P=0.008）。此外，在最终治疗后4周时，meibum质量和可表达性评分显着改善（均P<0.001）。其他变量,如眼压和视力，治疗后不受影响。
UNASSIGNED：IPL治疗和MGX的组合通过改善睑板腺功能，提供了一种低风险和有效的选择，可以降低复发性睑板腺的复发率。IPL-MGX可考虑用于切除后复发或难治性病例的一线治疗。
UNASSIGNED：纳入了用IPL-MGX治疗的42例连续复发性结束症病例（35例患者）。所有患者最初都进行了刮除术切除。病灶切除后一周，IPL-MGX进行至少3次。另一组年龄和性别匹配的复发性结束炎连续病例，接受了刮宫切除术的人，但是没有IPL-MGX治疗，收集以计算复发率。在IPL-MGX治疗前和最终治疗后1个月测量治疗效果和安全性。
UNASSIGNED：大多数患者接受4次IPL-MGX治疗（20例；57.1%）或3次IPL-MGX治疗（10例；28.6%），与无IPL-MGX病例的复发性结束症相比，复发率较低，为11.4％（45.6％，P<0.001)。最终治疗后4周，NIBUT从3.9±1.8s显着延长至5.1±1.7s（P=0.001）。同样，与基线相比，平均TMH评分改善且具有统计学意义(0.17±0.07vs.0.21±0.09；P=0.008）。此外，在最终治疗后4周时，meibum质量和可表达性评分显着改善（均P<0.001）。其他变量,如眼压和视力，治疗后不受影响。
UNASSIGNED：IPL治疗和MGX的组合通过改善睑板腺功能，提供了一种低风险和有效的选择，可以降低复发性睑板腺的复发率。IPL-MGX可考虑用于切除后复发或难治性病例的一线治疗。
